Abstract
Tardive dyskinesia (TD), a syndrome of involuntary hyperkinetic movements, purportedly involves the development of dopamine (DA) receptor hypersensitivity following long-term receptor blockade with neuroleptic drugs. It has been proposed that througn a process of receptor hypersensitivity modification, TD can be treated by reversing the receptor hypersensitivity with DA agonists. Thirteen patients with TD were treated for 4–8 weeks with levodopa plus benserazide, a peripheral decarboxylase inhibitor (Madopar, Roche, Basel, Switzerland) over a wide dose range corresponding to 3.0–9.0 g/day levodopa. Drug effects was assessed by blind evaluations of randomly sequenced videotapes made before, during, and for 6 weeks following treatment. TD scores moderately increased during levodopa. After the drug was discontinued, TD scores returned to pretreatment baseline levels without further improvement in those patients receiving concurrent neuroleptic medications (N=9), but in the neuroleptic-free patients TD scores decreased 25% in three patients and were resolved in one younger patient. Psychological effects of depression or increased psychotic symptoms occurred at higher drug doses. These results do not support the proposal that receptor sensitivity modification with levodopa is an effective therapeutic approach to TD, though selected patient and drug treatment variables, including other DA agonists, are considerations for further investigation.
Similar content being viewed by others
References
Alpert M, Friedhoff AJ (1980) Clinical application of receptor modification treatment. In: Fann WE, Smith RC, Davis JM, Domino EF (eds) Tardive dyskinesia Spectrum, New York, pp 471–473
Alpert M, Diamond F, Friedhoff AJ (1976) Tremorgraphic studies in tardive dyskinesia. Psychopharmacol Bull 12:5–7
Baldessarini RJ, Cole JO, Davis JM, Gardos G, Preskorn SH, Simpson GM, Tarsy D (eds) (1980) Tardive dyskinesia: A task force report. American Psychiatric Association, Washington, DC
Burt DR, Creese I, Snyder SH (1976) Antischizophrenic drugs: Chronic treatment elevates dopamine receptor binding in brain. Science 196:326–328
Carlson KR, Eibergen RD (1976) Susceptibility to amphetamine-elicited dyskinesias following chronic methadone treatment in monkeys. Ann NY Acad Sci 281:336–349
Casey DE (1981) Responses to dopamine agonists before, during, and after neuroleptic treatment. In: Perris C, Struwe G, Jansson G (eds) Biological psychiatry 1981: Developments in psychiatry, vol 5. Elsevier-North Holland Biomedical. New York, pp 833–836
Casey DE, Gerlach J, Christensson E (1980) Behavioral aspects of dopamine receptor hypersensitivity in primates. Prog Neuropsychopharmacol (Suppl): 110, 101
Casey DE, Gerlach J, Korsgaard S (1981) Clinical pharmacological approaches to evaluating tardive dyskinesia. In: Usdin E, Dahl S, Gram LF, Lingjaerde O (eds) Clinical pharmacology in psychiatry: Neuroleptic and antidepressant research. MacMillan, New York, pp 369–383
Christensen AV, Hyttel J (1982) Prolonged treatment with the GABA agonist THIP increases dopamine receptor binding more than it changes dopaminergic behaviour in mice. Drug Dev Res (in press)
Christensen AV, Fjalland B, Nielsen IM (1976) On the supersensitivity of dopamine receptors induced by neuroleptics. Psychopharmacology 48:1–6
Clow A, Jenner P, Marsden CD (1979) Changes in dopamine-mediated behavior during 1 year's neuroleptic administration. Eur J Pharmacol 57:365–375
Clow A, Theodorou A, Jenner P, Marsden CD (1980) Cerebral dopamine function in rats following withdrawal from 1 year of continuous neuroleptic administration. Eur J Pharmacol 63:145–157
Crane GE (1973) Persistent dyskinesia. Br J Psychiatry 122:395–405
Crow TJ, Cross AJ, Johnstone EC, Owen F, Owens DGC, Waddington JL (1981) Tardive dyskinesia: Disease process or drug effect? In: Perris C, Struwe G, Jansson G (eds) Biological psychiatry 1981: Developments in psychiatry, vol 5. Elsevier-North Holland Biomedical, New York, pp 860–864
Ezrin-Waters C, Seeman P (1978) l-Dopa reversal of hyperdopaminergic behavior. Life Sci 22:1027–1032
Friedhoff AJ (1977) Receptor sensitivity modification (RSM): A new paradigm for the potential treatment of some hormonal and transmitter disturbances. Comp Psychiatry 18:309–317
Friedhoff AJ, Bonnet K, Rosengarten H (1977) Reversal of two manifestations of dopamine receptor supersensitivity by administraion of l-Dopa. Res Commun Chem Pathol Pharmacol 16: 411–423
Gerlach J (1979) Tardive dyskinesia. Dan Med Bull 26:209–245
Klawans HL (1973) The pharmacology of tardive dyskinesia. Am J Psychiatry 130:82–86
Klawans HL, Rubovits R (1972) An experimental model of tardive dyskinesia. J Neural Transm 33:235–246
Krogsgaard-Larsen P, Johnstone GAR, Lodge D, Curtis DR (1977) A new class of GABA agonists. Nature 268:53–55
Smith JM, Baldessarini RJ (1980) Changes in prevalence, severity, and recovery in tardive dyskinesia with age. Arch Gen Psychiatry 37:1368–1373
Tamminga CA, Chase TN (1980) Bromocriptine and CF 25-397 in the treatment of tardive dyskinesia. Arch Neurol 37:204–205
Tarsy D, Baldessarini RJ (1974) Behavioral supersensitivity to apomorphine following chronic treatment with drugs which interfere with synaptic function of catecholamines. Neuropharmacology 13:927–940
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Casey, D.E., Gerlach, J. & Bjørndal, N. Levodopa and receptor sensitivity modification in tardive dyskinesia. Psychopharmacology 78, 89–92 (1982). https://doi.org/10.1007/BF00470596
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00470596